Switching from daily human growth hormone to once-weekly TransCon growth hormone treatment resulted in similar safety and efficacy outcomes in pediatric patients.
Endocrinology Advisor spoke with Dr Andrew Dauber about the possible benefits of genetic testing for diagnosing short stature.
Investigators sought to improve growth-monitoring programs by examining existing algorithms and examined the effect of using WHO vs national growth charts on algorithm performance.
The guidelines focused on idiopathic short stature, growth hormone deficiency, and primary IGF-I deficiency.
The FDA has approved the FlexPro PenMate is intended for users of Norditropin, which is indicated for patients with growth hormone-related disorders, who prefer hidden needles during injection.
Ferring announced that the FDA has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet).
Patients with growth hormone deficiency reaped significant benefits in quality of live over the long term.
